PDCD1 and non-small cell lung carcinoma: Survival analyses conducted on a retrospective cohort of 250 ICI-treated patients with NSCLC revealed that among patients treated with the PD-1 inhibitor pembrolizumab alone, those with high CTAB demonstrated significantly better overall survival than those treated with pembrolizumab in combination with chemotherapy.